

# *Cd33* Cas9-KO Strategy

**Designer:**

**Huan Fan**

**Reviewer:**

**Huan Wang**

**Design Date:**

**2020-1-13**

# Project Overview

**Project Name**

*Cd33*

**Project type**

**Cas9-KO**

**Strain background**

**C57BL/6JGpt**

# Knockout strategy

This model will use CRISPR/Cas9 technology to edit the *Cd33* gene. The schematic diagram is as follows:



- The *Cd33* gene has 6 transcripts. According to the structure of *Cd33* gene, exon1-exon3 of *Cd33-203* (ENSMUST00000205503.1) transcript is recommended as the knockout region. The region contains start codon ATG. Knock out the region will result in disruption of protein function.
- In this project we use CRISPR/Cas9 technology to modify *Cd33* gene. The brief process is as follows: CRISPR/Cas9 system

- According to the existing MGI data, Mice homozygous for disruptions in this gene show slight reductions in mean erythrocyte count and hematocrit and increased concentration of blood aspartate aminotransaminase. There is also a hyporesponsiveness to induced peritonitis and a weaker IL-6 response to LPS-induced systemic inflammation.
- The *Cd33* gene is located on the Chr7. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
- This Strategy is designed based on genetic information in existing databases. Due to the complexity of biological processes, all risk of the gene knockout on gene transcription, RNA splicing and protein translation cannot be predicted at the existing technology level.



# Gene information (NCBI)

## Cd33 CD33 antigen [Mus musculus (house mouse)]

Gene ID: 12489, updated on 31-Jan-2019

### Summary




<b>Official Symbol</b>	Cd33 provided by <a href="#">MGI</a>
<b>Official Full Name</b>	CD33 antigen provided by <a href="#">MGI</a>
<b>Primary source</b>	<a href="#">MGI:MGI:99440</a>
<b>See related</b>	<a href="#">Ensembl:ENSMUSG000000004609</a>
<b>Gene type</b>	protein coding
<b>RefSeq status</b>	VALIDATED
<b>Organism</b>	<a href="#">Mus musculus</a>
<b>Lineage</b>	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus
<b>Also known as</b>	Siglec-3, gp67
<b>Expression</b>	Broad expression in liver E18 (RPKM 4.3), mammary gland adult (RPKM 4.2) and 27 other tissues <a href="#">See more</a>
<b>Orthologs</b>	<a href="#">human</a> <a href="#">all</a>

# Transcript information (Ensembl)


The gene has 6 transcripts,all transcripts are shown below:

Name	Transcript ID	bp	Protein	Biotype	CCDS	UniProt	Flags
Cd33-203	<a href="#">ENSMUST00000205503.1</a>	5728	<a href="#">334aa</a>	Protein coding	<a href="#">CCDS21173</a>	<a href="#">Q63994</a>	TSL:1 GENCODE basic APPRIS P3
Cd33-201	<a href="#">ENSMUST00000004728.11</a>	1962	<a href="#">403aa</a>	Protein coding	<a href="#">CCDS52224</a>	<a href="#">Q63994</a>	TSL:1 GENCODE basic APPRIS ALT2
Cd33-202	<a href="#">ENSMUST00000039861.6</a>	1791	<a href="#">334aa</a>	Protein coding	<a href="#">CCDS21173</a>	<a href="#">Q63994</a>	TSL:1 GENCODE basic APPRIS P3
Cd33-205	<a href="#">ENSMUST00000206371.1</a>	933	<a href="#">240aa</a>	Protein coding	-	<a href="#">A0A0U1RNJ9</a>	CDS 5' incomplete TSL:5
Cd33-204	<a href="#">ENSMUST00000205687.1</a>	2376	No protein	Retained intron	-	-	TSL:1
Cd33-206	<a href="#">ENSMUST00000206977.1</a>	402	No protein	lncRNA	-	-	TSL:2

The strategy is based on the design of *Cd33-203* transcript,The transcription is shown below



# Genomic location distribution






# Protein domain



# Mouse phenotype description(MGI )



*Phenotypes affected by the gene are marked in blue. Data quoted from MGI database(<http://www.informatics.jax.org/>).*

According to the existing MGI data, Mice homozygous for disruptions in this gene show slight reductions in mean erythrocyte count and hematocrit and increased concentration of blood aspartate aminotransaminase. There is also a hyporesponsiveness to induced peritonitis and a weaker IL-6 response to LPS-induced systemic inflammation.

If you have any questions, you are welcome to inquire.

Tel: 400-9660890

